Introduction
In the United States, diabetes is the leading cause of end-stage renal disease (ESRD), which is kidney failure treated with dialysis or transplantation (1) . The prevalence of diabetes among American Indians/Alaska Natives (AI/AN) in the United States in 2012 (15.9%) was higher than that among non-Hispanic blacks (blacks) (13.2%), Hispanics (12.8%) or non-Hispanic whites (whites) (7.6%) during 2010-2012 (2) . Diabetes accounts for 44% of new cases of ESRD (diabetes-associated ESRD [ESRD-D]) in the overall U.S. population and for 69% among AI/AN (1) . Prevention or delay of ESRD-D involves control of blood pressure and blood glucose, early identification and monitoring of kidney disease, and use of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) in patients with albuminuria (3, 4) . This report presents trends in ESRD-D incidence for AI/AN Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives -United States, 1996-2013 coverage after 90 days of ESRD treatment, only data on patients who have been treated for at least 90 days are included in the data set (1) . For each year studied, USRDS data were used to determine the number of adults aged ≥18 years in the United States who began treatment (dialysis or kidney transplantation) for ESRD-D. Data were analyzed for AI/AN, white, black, and Asian racial groups, which include persons of Hispanic and non-Hispanic origin. Data for persons of Hispanic origin were analyzed separately.
ESRD-D incidence was calculated using the number of newly treated ESRD-D cases and two population estimates for each racial and ethnic group: 1) total population from the U.S. Census during 1996-2013, and 2) population with diagnosed diabetes during 2006-2013.
The number of AI/AN with diagnosed diabetes was calculated using age-and sex-specific prevalence estimates from the Indian Health Service (IHS) National Data Warehouse during 2006-2013 and multiplying them by annual bridged single race population estimates for AI/AN from the U.S. Census; 2006 was the first year for which consistent prevalence data are available. The IHS National Data Warehouse includes patient registration and encounter data from IHS facilities, tribally operated health programs, and urban Indian (I/T/U) health systems.* These facilities serve approximately 2.2 million AI/AN persons who belong to 567 federally recognized tribes in 36 states. † Diabetes cases were identified using diagnosis codes 250.0-250.93 from the International Classification of Diseases, Ninth revision, Clinical Modification. Patients were considered to have diagnosed diabetes if they had at least two health care visits with a diabetes diagnosis code reported during the fiscal year (5) . For the other racial and ethnic groups, estimates of the adult population with diagnosed diabetes (self-reported) were derived from the National Health Interview Survey. § ESRD-D incidence rates were age-adjusted based on the 2000 U.S. standard population, and joinpoint regression was used to analyze trends (6, 7) . Each trend segment is described by an annual percentage change (APC) with a 95% confidence interval (CI), and the trend for the entire study period is described by the average annual percentage change (AAPC). The rate of change for linear trends was tested to determine whether it was significantly different from zero. Results were considered significant if the p value was <0.05.
Measures of care for AI/AN with diabetes were obtained from the IHS Diabetes Care and Outcomes Audit (Audit), including prescription of ACE inhibitors and ARBs; blood pressure; hemoglobin A1C to assess glucose control; and urine albumin-to-creatinine ratio testing for identifying and monitoring diabetic kidney disease. The Audit is an annual process for assessing diabetes care and health outcomes for AI/AN with diagnosed diabetes who receive care at I/T/U facilities, tracking performance on several dozen diabetes care measures and prevalence of several diabetes complications, including kidney disease. ¶
Results
Among AI/AN adults, age-adjusted ESRD-D incidence per 100,000 population increased, but not significantly, from 57. pressure among >101,000 AI/AN in the Audit with diabetes and hypertension was 133/76 mmHg, below the target of <140/90. † † Average hemoglobin A1C levels in AI/AN with diabetes decreased 10% from 1996 to 2014, from 9.0% to 8.1% (9) . Finally, urine albumin-to-creatinine ratio testing was performed in 50% of AI/AN aged ≥65 years with diabetes in 2013, increasing to 62% by 2016. In the general Medicare diabetes population aged ≥65 years, the rate of urine albumin testing was 40% in 2013 (1).
Conclusions and Comment
Among AI/AN adults, age-adjusted ESRD-D incidence decreased 54% during 1996-2013; by 2013, among adults with diabetes, the ESRD-D rate was the same in AI/AN as in whites. This decline is especially remarkable given the well-documented health and socioeconomic disparities in the AI/AN population, including poverty, limited health care resources, and disproportionate burden of many health problems (10) . The findings in this report are consistent with other studies among AI/AN nationwide and among Pima Indians in the Southwest, which concluded that improvements in blood pressure, blood glucose, and the use of ACE inhibitors and ARBs played a significant role in the decline of ESRD-D in these populations (11, 12) .
The decrease of ESRD-D in AI/AN with diabetes was likely the result of improvements in both process and outcome measures presented in this report. Prescription of ACE inhibitors and ARBs in AI/AN with diabetes increased 76% from 1997 to 2002. In 2014, prescription of these medications among AI/AN with diabetes was 36% higher than for the overall U.S. population with diabetes (8) . Similarly, among persons with diabetes aged ≥65 years, the rate of urine albumin-to-creatinine ratio testing is 55% higher in AI/AN compared with Medicare beneficiaries (1). Outcome measures are also positive, including blood pressure control in AI/AN with diabetes and hypertension and improved glycemic control overall. Establishing and sustaining these favorable trends in diabetes management and prevention of ESRD-D are related to population and team-based approaches to diabetes management undertaken by the IHS. † † American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017 Jan; 40 (Supplement 1): S1-S135. Starting in the mid-1980s, IHS implemented systematic approaches to diabetes care that have contributed to the outcomes presented here (13, 14) . These approaches were informed by public health and population management principles, which focus not just on short-term outcomes for individual patients who seek care, but also long-term outcomes, costs, disparities, and wellness of the entire community (15) . These approaches include multidisciplinary team-based, coordinated clinical care and education, community outreach, and tracking of clinical process and outcomes data at the local, regional, and national levels (9) . This IHS system of diabetes care enabled I/T/U sites to successfully and consistently deliver evidence-based interventions that reduce ESRD-D risk factors. In 1986, IHS developed its first Diabetes Standards of Care to disseminate evidence-based recommendations aimed at improving diabetes care for AI/AN (13) . These standards were revised in the early 1990s to include assessment and treatment of CKD (16) . IHS was one of the first systems to establish routine reporting of the estimated glomerular filtration rate, yearly monitoring of urine albumin excretion, and prescription of ACE inhibitors and ARBs (14) . Both of these classes of therapeutic agents have been shown to prevent or delay the development of ESRD-D in patients with albuminuria, independent of their effects in reducing blood pressure (4, 17) .
As data collection and analysis are fundamental components of an effective diabetes care system, IHS first implemented the Diabetes Care and Outcomes Audit in 1986 at several sites, and in 1997, developed a centralized, national database (18) . Successful implementation of evidence-based clinical interventions as documented by the Audit might explain in part the decline in ESRD-D incidence in AI/AN adults with diabetes. IHS has made other improvements in diabetes care by developing clinical education programs and tools; culturally relevant patient education materials; and population-based management tools in the IHS electronic health record (9, 14, 19) . I/T/U case managers help coordinate in-house care as well as referrals for specialty services, to facilitate greater care continuity than in more fragmented systems. § § I/T/U facilities also support diabetes care and education by using public health nurses and community health workers to provide outreach and education to the community. ¶ ¶, *** In 1997, Congress established the Special Diabetes Program for Indians (SDPI) (9) . The SDPI provides much-needed funding to 301 I/T/U sites to implement interventions which reduce risk factors for diabetes and its complications, including ESRD-D (Table 2) used by IHS to improve its national program for disseminating evidence-based interventions and providing training, tools for data collection and analysis, and support to diabetes programs in AI/AN communities across the country. Because of SDPI, the partnership of IHS and I/T/U programs is stronger, and together they provide a comprehensive public health-oriented national program that has demonstrated success in addressing the diabetes epidemic and reducing complications such as ESRD-D (9). The findings in this report are subject to at least five limitations. First, the data are for persons receiving ESRD treatment as reported to CMS and do not include patients who refused treatment, those who died before receiving treatment, or those whose treatment was not reported to CMS. Second, primary diagnosis was obtained from the CMS Medical Evidence Report and was based on a physician's assessment of the patient, which could be influenced by the physician's awareness of diabetes prevalence among AI/AN. Third, differential classification of AI/AN race in the USRDS, U.S. Census, and IHS data systems could result in over-or underestimation of the actual incidence of ESRD-D in this population. Fourth, IHS data on diabetes prevalence might not be representative of the total AI/AN population and might result in over-or underestimation of the number of AI/AN with diabetes in the United States and, therefore, the incidence of ESRD-D. Although these biases might have affected incidence estimates, trends in incidence would not be affected if the biases remained consistent over time. Finally, the data on diabetes measures reflect care provided to AI/AN who access the I/T/U system and cannot be generalized to AI/AN who do not.
ESRD-D is a disabling and costly condition associated with high mortality. 
